Aberrant function of MYC is a feature of about 60% of all human cancers; MYC translocations are present in most Burkitt’s lymphomas [11–13] and in 5–15% of DLBCL [14]; MYC gains or amplification and rarely MYC translocation were complexively detected in 36% of MCL [15]. This evidence concerns the gene MYC and mantle cell lymphoma.